Today's Rundown Featured Story | | | Tuesday, November 20, 2018 LEO Pharma has signed a research collaboration deal with PellePharm that commits up to $760 million for late-stage trials and includes an option for LEO to acquire the small rare disease company outright at some point in the future. |
|
|
| This week's sponsor is FierceBiotech. | |  | |
Top Stories Tuesday, November 20, 2018 Fresh from a $200 million fundraising that pushed its valuation above $7 billion, Roivant Sciences has spent more money on its R&D portfolio, licensing a midstage drug for resistant bacteria from South Korea’s Intron Biotechnology. Tuesday, November 20, 2018 Enlivex Therapeutics is set to bag a Nasdaq listing through a reverse merger with BioBlast Pharma. News of the merger comes as Enlivex gears up for a multi-indication phase 2 and 3 trial push for its immunotherapy Allocetra. Wednesday, November 14, 2018 In 1848, the most famous Gold Rush in American history began at Sutter's Mill near present-day Coloma, California, shaping the US economic map forever. In those days, there were no scientific tools to guide prospectors in their search. Sites of previous finds were the starting point for what became, for many, a shattered dream. Monday, November 19, 2018 Eli Lilly VP Robert Brown is making the jump to serve as CEO of the skin disease-focused Brickell Biotech, as it prepares to move its lead candidate into phase 3 trials for excessive underarm sweating next year. Tuesday, November 20, 2018 Synthego has tapped Eurofins Genomics to distribute synthetic single guide RNA products from its CRISPRevolution line of genome-editing kits. The partnership adds Eurofins customers in 44 countries to Synthego’s market. Tuesday, November 20, 2018 A phase 3 trial of Stallergenes Greer’s treatment for house dust mite-induced allergic rhinitis has met its primary endpoint. The late-phase success sets Stallergenes up to file for FDA approval of oral immunotherapy STAGR320. Tuesday, November 20, 2018 The FDA, which expected to approve or deny Sage Therapeutics’ brexanolone next month, has pushed that decision off to March 19 so it can finalize risk evaluation and mitigation strategies to improve the treatment’s safety. Enrollment Showcase | | | Sponsored by: Biotech Primer BioBasics is an intensive two-day course starting with a review of the healthcare sectors and the scientific concepts required for understanding the biopharma industry, then delves into the cause of genetic and infectious disease, diagnostics and strategies used to mitigate disease and finally the latest innovations in biopharma are explained. Register today! |
|
|
Resources Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Reprints Desk, Inc. Learn how to fast-track your research workflows! Sponsored by: Veeva Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes. Sponsored by: Oracle Health Sciences New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data. Sponsored by: Veradigm New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management Sponsored by: Signals Analytics What does data tell us about the future of cell & gene therapy? Sponsored by: Patheon, part of Thermo Fisher Scientific Download the whitepaper to learn more. Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Catalent In the United States, it takes an average of 12 years for an experimental drug to travel from the laboratory to a patient’s medicine cabinet. The average cost to research and develop a successful drug is approximately $2.6 billion. Sponsored by: Catalent Today’s scientists are under significant time pressure to accelerate their compound from discovery to the clinic. Such pressure can often lead research organizations to adopt short-term thinking and overlook the downstream realities of drug development. Sponsored by: Catalent What is the fastest way to success? It is critical that drug developers execute several elements related to planning, investment, and understanding of the risks, risk tolerance, and pitfalls inherent in the drug development program. Sponsored by: Forte Research Systems Discover what over 800 of your peers think about technology's impact on clinical trial operations. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Sponsored by: Catalent Develop a basic understanding of principles and concepts of bioavailability of oral drugs. | 
